Condition: Small Cell Neuroendocrine Carcinoma of Bladder · Bladder Cancer · Urothelial Carcinoma Bladder · Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
This is a single arm, Phase II trial involving the use of atezolizumab plus platinum and etoposide for patients with locally advanced urothelial cancer. The primary goal of this trial is to assess the pathologic complete response rate at cystectomy in patients after being treated with a combination therapy of atezolizumab, platinum, and etoposide.
This description comes directly from the study's public registry record.
Deborah Schwartz, RN · 410-502-4523 · dschwa27@jhmi.edu
Always discuss trial participation with your own doctor first.
| Johns Hopkins University: Sibley Memorial Hospital | Washington D.C., District of Columbia, United States | Recruiting |
| Johns Hopkins University: Sidney Kimmel Comprehensive Cancer Center | Baltimore, Maryland, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05312671